Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Emory University
Study ID
NCT01435395
Phase
PHASE1
Status
Completed

Conditions

  • Glioblastoma Multiforme

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent glioblastoma multiforme. Patients requiring anti-epileptic medications will have to be at least 10 days off EIAEDs. Only non-EIAEDs are accepted.

Key Dates

First listed
Sep 16, 2011
Start date
Dec 31, 2011
Status verified
Apr 2016
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Therapy
    Therapy with temozolomide, bevacizumab and bortezomib

Primary Outcome Measure

Determination of progressive disease, complete or partial responses [ Time Frame: 6 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Emory University Hospital MidtownAtlantaGeorgia30308-
Emory University Winship Cancer InstituteAtlantaGeorgia30322-

Find similar trials in Atlanta, GA

By research site
Emory University Hospital Midtown· Atlanta, GAEmory University Winship Cancer Institute· Atlanta, GA

Related Studies